IOANA RUIZ ARRUZA-rekin lankidetzan egindako argitalpenak (7)

2021

  1. Anti-phospholipid antibodies do not predict damage in SLE patients in the 21st century-an observational study from the Lupus-Cruces cohort

    Rheumatology (Oxford, England), Vol. 61, Núm. 1, pp. 249-257

2020

  1. Seventy years after Hench’s Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus

    Lupus, Vol. 29, Núm. 10, pp. 1155-1167

2019

  1. Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts

    Autoimmunity Reviews, Vol. 18, Núm. 9

2018

  1. Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults

    Rheumatology (Oxford, England)

  2. Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study

    Arthritis Care and Research, Vol. 70, Núm. 4, pp. 582-591

2015

  1. Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis

    Autoimmunity Reviews, Vol. 14, Núm. 10, pp. 875-879

2014

  1. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus

    Rheumatology (United Kingdom), Vol. 53, Núm. 8, pp. 1470-1476